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Background: CFRD is believed to be consequence of destruction of insulin-
producing beta cells by ﬁbrous tissue. The fact that not all pancreatic insufﬁcient
CF patients have diabetes (DM) may relate to autoimmunity as an additional
aetiological factor. We aimed to determine HLA class II type and levels of anti-
islet autoantibodies (AAb) in CF patients with and without DM and compare with
that of long standing type 1 DM patients (T1DM) and controls. Materials and
Methods: We studied 30 pancreatic insufﬁcient CF patients, mean age 26 (17−42 y)
14 had CFRD for >1 year, 16 had no evidence of DM. HLA class II typing was
performed and anti-islet AAb to glutamic acid decarboxylase (GAD) and protein
tyrosine phosphatase (IA-2) measured. AAb prevalence was compared to that in
an age-matched group with T1DM (>10 years) and controls. AAb were positive if
GAD 14 and IA-2 6 WHO units/ml.
Results: CF groups were matched for age and gender. There were no differences
in BMI or exocrine pancreatic function (assessed by requirement of oral lipase).
Frequency of DM susceptibility haplotypes HLA DR3-DQA1*0501-DQB1*0201
(DQ2) or DR4-DQA1*0301-DQB1*0302 (DQ8) was not increased in CF. No CF
patient carried high risk genotype DQ2/DQ8 compared to 5 of 12 T1DM p= 0.001.
There were no differences in frequency of HLA alleles between CF groups. None
of the CF groups or controls were positive for GAD or IA-2 whereas 9 of 12 T1DM
had positive responses p< 0.0001.
Conclusions: There was no increase in HLA class II haplotypes associated with
T1DM in CF groups. CF patients with and without DM did not express anti-islet
AAb. The development of CFRD does not appear to be related to HLA class II
genotype or anti-islet autoimmunity.
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Introduction: Multiple antibiotic allergies are a major clinical problem affecting
patients with cystic ﬁbrosis (CF) often necessitating hospital admission, restricting
treatment, and resulting in patients being refused lung transplantation. The incidence
of allergic reactions to beta-lactams are three times more common in patients
with CF and are often delayed [1]. In our adult CF population 32% have a history of
reactions to tazocin, 29% to ceftazidime, 13% to meropenem, and 7% are allergic
to three or more antibiotics. The mechanisms underlying these adverse antibiotic
reactions have never been identiﬁed.
Methods:We assessed 25 patients, all of whom have previously had hypersensitivity
reactions to at least 3 beta-lactam antibiotics. The reactions consisted of rash (48%),
arthralgia (19%), facial swelling (15%), pruritis (15%), and fever (3%). Skin prick
tests were performed using benzylpenicillin, tazocin, meropenem, aztreonam, and
ceftazidime. If skin prick tests were negative intradermal injections were performed.
The intradermal sites were read at 24 and 48 hours.
Results: No patient developed a positive skin prick reaction. One patient developed
a systemic reaction consisting of pruritis and vomiting 15 minutes after intradermal
injection with ceftazidime, however, there was no positivity in his skin tests. All
intradermal sites were negative at 24 and 48 hours.
Discussion: These ﬁndings suggest that the reactions are unlikely to be due to an
immediate IgE mediated (Type I) reaction, or a delayed T cell mediated (Type IV)
hypersensitivity reaction.
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The mechanisms linking CFTR dysfunction to pulmonary disease in cystic ﬁbrosis
remain unclear. Here, we show that Pseudomonas aeruginosa LPS induces bronchial
hyperactivity (BHR), mucus overproduction and MUC5AC mucin overexpression
in cftr−/− compared to cftr+/+ mice. This was preceded by an enhanced lung
inﬂammation, cytosolic phospholipase A2a (cPLA2a) activation and arachidonic
acid (AA) release. Mucus production was induced by intra-tracheal instillation
of AA and abrogated either by disruption of the cPLA2a gene or treatment of
mice with a cPLA2a inhibitor. However, disruption of cPLA2a gene failed to
interfere with the induction of BHR or lung inﬂammation by LPS. Enhanced
cPLA2a activation was evidenced in bronchial explants from CF compared to non-
CF patients. MUC5AC production was increased in human epithelial cell line from
CF patients as compared to control cells, and abrogated by cPLA2a inhibition. We
suggest CFTR alteration induces mucus overproduction through a process involving
abnormal cPLA2a activation. This enzyme, however, had no impact on BHR or
lung inﬂammation. We propose a potential therapeutic role for cPLA2a inhibitors
in reducing bronchial mucus overproduction in CF.
Supported by: Institut Pasteur, Vaincre La Mucoviscidose, Inserm.
212 Atopic background as a risk factor for allergic bronchopulmonary
aspergillosis in cystic ﬁbrosis (CF) patients
A. Katelari1, M. Kanariou2, D. Hatzis1, I. Inglezos1, S. Doudounakis1. 1CF
center, “Aghia Sophia” Children’s Hospital, Athens, Greece; 2Immunology, “Aghia
Sophia” Children’s Hospital, Athens, Greece
Introduction: Allergic bronchopulmonary aspergillosis (ABPA) is an immunologic
reaction to antigens of Aspergillus mainly fumigatus (AF), that commonly worsens
the prognosis of cystic ﬁbrosis (CF), more than chronic or intermittent pseudomonas
infection.
Aim of the study: To ﬁnd out the correlation, if any, between atopy and ABPA in
CF patients attending the CF pediatric center in Athens, Greece.
Material & methods: Chart review of 376 patients (age 0 to 22 years old; 186
males, 190 females), followed in our center over the past seven years. Atopic
background was considered when the total IgE level was 2SD than the expected
range irrespective of the results of RAST for various speciﬁc antigens  class II
(positive RAST). Diagnosis of ABPA was based on standard criteria.
Results: ABPA diagnosis was documented in 24 of the 376 CF patients (6.4%).
Notably, 20 of the ABPA CF patients (83.3%) were atopic and were also responsive
to more than two allergens (18 [90%] were positive for fungi other that Aspergillus,
eight [40%] to various aeroallergens, and four [20%] to food antigens). Of the
remaining 352 patients, 46 (13%) had evidence of a possible atopic background,
14 (30%) of them exhibiting IgE> 500 IU and positive RAST to various antigens.
It was, therefore, apparent that the incidence of ABPA in this CF population was
signiﬁcantly higher among patients with atopy (p< 0.001).
Conclusions: Notwithstanding the relatively low number of enrolled patients, the
potential association between atopy and ABPA in CF may have serious therapeutic
implications and warrants further study.
